METHODS AND MATERIALS FOR TREATING CANCER

This document provides methods and materials for treating cancer. For example, methods and materials for treating cancer using combinations of antigens are provided. For example, VSV vectors designed to express a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal (e.g., a human). In some cases, VSV vectors designed to express a BRAF antigen, a TOPO-lla antigen, and a YB-I antigen can be used to reduce the number of cancer cells (e.g., skin melanoma cells) within a mammal (e.g., a human). The composition can comprise less than 50 separate nucleic acid molecules. 1. A composition comprising nucleic acid encoding a GNAQ antigen , a TYRP1 antigen , and an N-RAS antigen , wherein said composition comprises less than 100 separate nucleic acid molecules.2. The composition of claim 1 , wherein said composition comprises a nucleic acid molecule encoding said GNAQ antigen claim 1 , a nucleic acid molecule encoding said TYRP1 antigen claim 1 , and a nucleic acid molecule encoding said N-RAS antigen.38-. (canceled)9. A method of treating cancer within a mammal claim 1 , wherein said method comprises administering to said mammal a composition comprising nucleic acid encoding a GNAQ antigen claim 1 , a TYRP1 antigen claim 1 , and an N-RAS antigen claim 1 , wherein said composition comprises less than 100 separate nucleic acid molecules.10. The method of claim 9 , wherein said cancer is a melanoma.11. The method of claim 9 , wherein said mammal is a human.12. The method of claim 9 , wherein said composition comprises a nucleic acid molecule encoding said GNAQ antigen claim 9 , a nucleic acid molecule encoding said TYRP1 antigen claim 9 , and a nucleic acid molecule encoding said N-RAS antigen.1318-. (canceled)19. A composition comprising nucleic acid encoding a BRAF antigen claim 9 , a TOPO-IIα antigen claim 9 , and a YB-1 antigen claim 9 , wherein said composition comprises less than ...

METHODS AND MATERIALS FOR TREATING CANCER

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided. In general, one aspect of this document features a composition comprising, or consisting essentially of, nucleic acid encoding HIF-2a, SOX-10, C-MYC, and TYRP-1, wherein the composition comprises less than 100 separate nucleic acid molecules.

Methods and materials for treating cancer

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided.

METHODS AND MATERIALS FOR TREATING CANCER

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided. 1. A method of treating an established tumor within a mammal , wherein said method comprises administering to said mammal a composition comprising nucleic acid encoding an N-RAS antigen , a TYRP1 antigen , and a CYT-C antigen , wherein said composition comprises less than 100 separate nucleic acid molecules.2. The method of claim 1 , wherein said tumor is a melanoma.3. The method of claim 1 , wherein said N-RAS antigen claim 1 , said TYRP1 antigen claim 1 , and said CYT-C antigen are VSV-expressed. This application is a divisional of U.S. application Ser. No. 14/385,240, filed Sep. 15, 2014, which is a National Stage application under U.S.C. §371 of International Application No. PCT/US2013/031953, filed Mar. 15, 2013, which claims the benefit of U.S. Provisional Application Ser. No. 61/611,387, filed Mar. 15, 2012. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.This invention was made with government support under grant numbers CA107082, CA130878, and CA132734 awarded by the National Institutes of Health. The government has certain rights in the invention.1. Technical FieldThis document relates to methods and materials for treating cancer. For example, this document relates to methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer. This document also relates to methods and materials for using combinations of antigens to treat cancer (e.g., melanoma).2. Background InformationCancer is a serious illness that affects many people every year. In general, there are several common methods for treating cancer: surgery, ...

Methods and materials for treating cancer

This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided.

Methods and materials for treating cancer

This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided.

Methods and materials for treating cancer

This document relates to methods and materials for treating a mammal having cancer. For example, compositions (e.g., vaccines) containing cells (e.g., tumor cells) expressing APOBEC3 which can be administered to a mammal (e.g., a human) having cancer to induce an immune response (e.g., an anti-tumor immune response) within the mammal are provided.

METHODS AND MATERIALS FOR TREATING CANCER

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided. 1. A method for identifying , from a nucleic acid library , a nucleic acid encoding an antigen having the ability , either alone or in combination with one or more other antigens , to stimulate an anti-cancer response , wherein said nucleic acid library is a library of virally-expressed nucleic acid members and has the ability to stimulate an anti-cancer response when administered to a mammal having cancer , wherein said method comprises:(a) contacting immune cells with an aliquot of said nucleic acid library to form a collection of virally infected cells, wherein said immune cells were obtained from a mammal that exhibited a reduction in the number of cancer cells following administration of a first nucleic acid library,(b) obtaining a cell from said collection of virally infected cells that has the ability to secrete a cytokine polypeptide, wherein said cell contains a nucleic acid member of said nucleic acid library, and(c) determining the sequence of said nucleic acid member of said cell, wherein said nucleic acid member is said nucleic acid encoding an antigen having the ability, either alone or in combination with one or more other antigens, to stimulate an anti-cancer response.2. The method of claim 1 , wherein said nucleic acid library is a cDNA library.3. The method of claim 1 , wherein said nucleic acid library is a VSV-expressed cDNA library.4. The method of claim 1 , wherein said immune cells were obtained from a mammal that exhibited a reduction in the number of cancer cells following administration of a first nucleic acid library.5. The method of claim 4 , wherein said first nucleic acid library is a cDNA library.6. The method of claim 4 , ...

ONCOLYTIC VIRUSES AND METHODS FOR USING ONCOLYTIC VIRUSES

This document relates to methods and materials for treating cancer. For example, engineered viruses (e.g., oncolytic viruses) encoding one or more inhibitors of apolipoprotein B editing complex 3B (APOBEC3B) polypeptide activity or expression and methods for using such viruses as an oncolytic agent (e.g., to treat cancer) are provided. For example, one or more engineered oncolytic viruses encoding one or more inhibitors of APOBEC3B polypeptide activity or expression can be administered to a mammal having cancer to treat that mammal. 1. A method for treating a mammal having cancer , wherein said method comprises administering a composition comprising an oncolytic virus to said mammal , thereby reducing the number of cancer cells within said mammal ,wherein said oncolytic virus comprises nucleic acid encoding an inhibitor of APOBEC3B polypeptide activity or expression, andwherein the level of cancer cell resistance development to said oncolytic virus within said mammal is reduced as compared to the level that develops in a comparable mammal administered a comparable oncolytic virus lacking said nucleic acid encoding said inhibitor.2. The method of claim 2 , wherein said mammal is a human.3. The method of claim 1 , where said cancer is selected from the group consisting of breast cancer claim 1 , brain cancer claim 1 , prostate cancer claim 1 , ovarian cancer claim 1 , lung cancer claim 1 , hepatocellular carcinoma claim 1 , pancreatic cancer claim 1 , kidney cancer claim 1 , melanoma claim 1 , bladder cancer claim 1 , colorectal cancer claim 1 , osteosarcoma claim 1 , myeloma claim 1 , leukemia claim 1 , and lymphoma.4. The method of claim 1 , wherein said oncolytic virus is selected from the group consisting of a vesicular stomatitis virus (VSV) claim 1 , a Maraba virus (MARAV) claim 1 , a herpes simplex virus (HSV) claim 1 , a vaccinia virus (VV) claim 1 , a measles virus (MV) claim 1 , and a poliovirus (PV).5. (canceled)6. The method of claim 1 , wherein said ...

Methods and materials for treating cancer

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided.

Materials and methods for treatment with oncolytic viruses and modified car t cells

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (OVs) in combination with an adoptive cell therapy (e.g., a chimeric antigen receptor T cell therapy) to alter one or more functions of a T cell and/or to enhance T cell expansion to treat cancer in a mammal (e.g., a human) are provided.

Methods and materials for treating cancer

Inducing immune-mediated tumor cell death

Methods and materials for treating cancer

Methods and materials for treating cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for using T cells (e.g., chimeric antigen receptor (CAR) T cells) and one or more antigenic compositions (e.g., one or more compositions including one or more antigens) to treat a mammal (

Materials and methods for treatment with oncolytic viruses and modified car t cells

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (OVs) in combination with an adoptive cell therapy (e.g., a chimeric antigen receptor T cell therapy) to alter one or more functions of a T cell and/or to enhance T cell expansion to treat cancer in a mammal (e.g., a human) are provided.

Methods and materials for treating cancer

This document provides methods and materials for treating cancer. For example, methods and materials for using oncolytic viruses (e.g., replication-competent vesicular stomatitis viruses) to treat cancer are provided. Replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses), nucleic acid molecules encoding a replication-competent oncolytic virus (e.g., replication-competent oncolytic vesicular stomatitis virus), methods for making replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses), methods for using replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses) to treat cancer, cancer neoantigens, nucleic acids encoding a cancer neoantigen, and methods for stimulating immune cells (e.g., cytotoxic T lymphocytes) to kill cancer cells also are provided.

Methods and materials for treating cancer

This document relates to methods and materials for treating a mammal having cancer. For example, compositions ( e.g., vaccines) containing cells ( e.g., tumor cells) expressing APOBEC3 which can be administered to a mammal ( e.g. , a human) having cancer to induce an immune response ( e.g. , an anti-tumor immune response) within the mammal are provided.

Methods and materials for treating cancer

This document relates to methods and materials for treating a mammal having cancer. For example, compositions ( e.g. , vaccines) containing cells ( e.g. , tumor cells) expressing APOBEC3 which can be administered to a mammal ( e.g ., a human) having cancer to induce an immune response ( e.g ., an anti-tumor immune response) within the mammal are provided.

Methods and materials for treating cancer

This document relates to methods and materials for treating a mammal having cancer. For example, compositions ( e.g., vaccines) containing cells ( e.g., tumor cells) expressing APOBEC3 which can be administered to a mammal ( e.g. , a human) having cancer to induce an immune response ( e.g. , an anti-tumor immune response) within the mammal are provided.

Methods and materials for treating cancer

This document provides methods and materials for treating cancer. For example, methods and materials for using oncolytic viruses (e.g., replication-competent vesicular stomatitis viruses) to treat cancer are provided. Replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses), nucleic acid molecules encoding a replication-competent oncolytic virus (e.g., replication-competent oncolytic vesicular stomatitis virus), methods for making replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses), methods for using replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses) to treat cancer, cancer neoantigens, nucleic acids encoding a cancer neoantigen, and methods for stimulating immune cells (e.g., cytotoxic T lymphocytes) to kill cancer cells also are provided.

Materials and methods for treatment with oncolytic viruses and modified car t cells

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (OVs) in combination with an adoptive cell therapy (e.g., a chimeric antigen receptor T cell therapy) to alter one or more functions of a T cell and/or to enhance T cell expansion to treat cancer in a mammal (e.g., a human) are provided.

Methods and materials for treating cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for using T cells (e.g., chimeric antigen receptor (CAR) T cells) and one or more antigenic compositions (e.g., one or more compositions including one or more antigens) to treat a mammal (e.g., a human) having cancer are provided.

Methods and materials for treating cancer

This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided.

Oncolytic viruses and methods for using oncolytic viruses

Compositions and methods for tissue specific gene regulation therapy

The invention relates to a recombinant nucleic acid vector comprising a first expression cassette comprising a first promoter operably linked to a nucleic acid sequence encoding a syncytium-inducing polypeptide, wherein the first expression cassette is flanked on either side by a site recognized by a recombinase. The invention also includes a second expression cassette comprising a tissue-specific promoter operably linked to a nucleic acid sequence encoding a recombinase. The invention also includes cells and compositions including these expression cassettes and methods of reducing tumor volume by expression of these expression cassettes.

Methods and materials for treating cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for using T cells (e.g., chimeric antigen receptor (CAR) T cells) and one or more antigenic compositions (e.g., one or more compositions including one or more antigens) to treat a mammal (e.g., a human) having cancer are provided.

Methods and materials for treating cancer

This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided.

Methods and materials for treating cancer

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using (a) APCs (e.g., dendritic cells) designed to release a viral vector that can infect a T cell (e.g., an infectious retroviral vector or an infectious lentiviral vector) and drive expression of an antigen receptor (e.g., a CAR) within that T cell and (b) an antigenic composition containing one or more antigens that can be presented to T cells within the mammal by APCs of the administered population and/or by other APCs within the mammal to produce dual specific CAR

Oncolytic viruses and methods for using oncolytic viruses

This document relates to methods and materials for treating cancer. For example, engineered viruses (e.g., oncolytic viruses) encoding one or more inhibitors of apolipoprotein B editing complex 3B (APOBEC3B) polypeptide activity or expression and methods for using such viruses as an oncolytic agent (e.g., to treat cancer) are provided. For example, one or more engineered oncolytic viruses encoding one or more inhibitors of APOBEC3B polypeptide activity or expression can be administered to a mammal having cancer to treat that mammal.

Oncolytic viruses and methods for using oncolytic viruses

This document relates to methods and materials for treating cancer. For example, engineered viruses (e.g., oncolytic viruses) encoding one or more inhibitors of apolipoprotein B editing complex 3B (APOBEC3B) polypeptide activity or expression and methods for using such viruses as an oncolytic agent (e.g., to treat cancer) are provided. For example, one or more engineered oncolytic viruses encoding one or more inhibitors of APOBEC3B polypeptide activity or expression can be administered to a mammal having cancer to treat that mammal.

Methods and materials for treating cancer

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using (a) APCs (e.g., dendritic cells) designed to release a viral vector that can infect a T cell (e.g., an infectious retroviral vector or an infectious lentiviral vector) and drive expression of an antigen receptor (e.g., a CAR) within that T cell and (b) an antigenic composition containing one or more antigens that can be presented to T cells within the mammal by APCs of the administered population and/or by other APCs within the mammal to produce dual specific CAR+ memory T cells are provided.

Methods and materials for treating cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for using T cells (e.g., chimeric antigen receptor (CAR) T cells) and one or more antigenic compositions (e.g., one or more compositions including one or more antigens) to treat a mammal ( e.g. , a human) having cancer are provided.

Methods and materials for treating cancer

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using (a) APCs (e.g., dendritic cells) designed to release a viral vector that can infect a T cell (e.g., an infectious retroviral vector or an infectious lentiviral vector) and drive expression of an antigen receptor (e.g., a CAR) within that T cell and (b) an antigenic composition containing one or more antigens that can be presented to T cells within the mammal by APCs of the administered population and/or by other APCs within the mammal to produce dual specific CAR+ memory T cells are provided.

Methods and vectors for controlling gene expression

Methods and materials for treating cancer

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided. In general, one aspect of this document features a composition comprising, or consisting essentially of, nucleic acid encoding HIF-2a, SOX-10, C-MYC, and TYRP-1, wherein the composition comprises less than 100 separate nucleic acid molecules.

Methods and vectors for controlling gene expression

Methods and materials for treating cancer

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using (a) APCs (e.g., dendritic cells) designed to release a viral vector that can infect a T cell (e.g., an infectious retroviral vector or an infectious lentiviral vector) and drive expression of an antigen receptor (e.g., a CAR) within that T cell and (b) an antigenic composition containing one or more antigens that can be presented to T cells within the mammal by APCs of the administered population and/or by other APCs within the mammal to produce dual specific CAR + memory T cells are provided.

Materials and methods for treatment with oncolytic viruses and modified CAR T cells

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (OVs) in combination with an adoptive cell therapy (e.g., a chimeric antigen receptor T cell therapy) to alter one or more functions of a T cell and/or to enhance T cell expansion to treat cancer in a mammal (e.g., a human) are provided.